Peptide Comparison
UlaritidevsThymosin Beta-4
A synthetic natriuretic peptide designed to help your heart pump better and remove excess fluid when you need it most.
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
Ularitide
As prescribed–As prescribed mg
Thymosin Beta-4
2–5 mg
Frequency
Ularitide
Once daily
Thymosin Beta-4
Twice weekly
Administration
Ularitide
Intravenous infusion
Thymosin Beta-4
Subcutaneous injection
Cycle Length
Ularitide
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset Speed
Ularitide
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
Ularitide
Strong human trials (Phase 3 or FDA approved)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Cardiovascular Support
Fluid & Electrolyte Balance
Kidney Protection
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
Ularitide
Molecular Formula
C145H234N52O44S3
Molecular Weight
3505.9
Half-Life
6-7 minutes (in circulation)
Bioavailability
100% (intravenous administration)
CAS Number
Not publicly assigned (proprietary compound)
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Applications
Best
suited for
Ularitide
Managing acute heart failure symptoms and fluid overload
Ularitide is particularly well-suited for individuals focused on managing acute heart failure symptoms and fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving oxygen delivery when your heart can't pump efficiently
Ularitide is particularly well-suited for individuals focused on improving oxygen delivery when your heart can't pump efficiently. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Protecting kidney function in critical heart patients
Ularitide is particularly well-suited for individuals focused on protecting kidney function in critical heart patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
Ularitide
Common
- Dizziness or lightheadedness
- Low blood pressure (hypotension)
- Headache
- Nausea
Uncommon
- Elevated potassium levels
- Worsening kidney function (transient)
- Allergic reactions at injection site
- Chest discomfort
- Irregular heartbeat (arrhythmia)
Serious
- Severe hypotension requiring intervention
- Worsening heart function in some patients
- Acute kidney injury (rare)
- Anaphylactic shock (very rare)
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
Ularitide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Not FDA approved
Safety Overview
Ularitide is a recombinant B-type natriuretic peptide approved in Europe for acute heart failure with safety data from Phase 3 trials showing favorable tolerability compared to placebo and nesiritide. Hypotension is the primary dose-limiting adverse effect, requiring baseline blood pressure assessment and careful hemodynamic monitoring during IV infusion. Natriuretic peptide class risks include worsening renal function in some patients and hypokalemia (electrolyte abnormalities from enhanced diuresis), necessitating electrolyte monitoring during acute phase therapy.
Contraindications
- xHypotension (dangerously low blood pressure)
- xCardiogenic shock without proper monitoring
- xSevere renal dysfunction in some cases
- xAllergy to synthetic peptides
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose Ularitide if...
- Managing acute heart failure symptoms and fluid overload
- Improving oxygen delivery when your heart can't pump efficiently
- Protecting kidney function in critical heart patients
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation